Blueprint Medicines’ Ayvakit: Capturing The ISM Niche (Rating Upgrade) (NASDAQ:BPMC)

Mast cell releasing histamine

Artur Plawgo/iStock via Getty Images

At a Glance

In my prior analysis of Blueprint Medicines (NASDAQ:BPMC), I had highlighted the company’s strong cash position and the potential impact of Ayvakit’s FDA approval on indolent systemic mastocytosis [ISM]. While the

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *